1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Live and Attenuated Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Live and Attenuated Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Live and Attenuated Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Live and Attenuated Vaccine Segment by Type
2.2.1 Pediatric Vaccine
2.2.2 Adult Vaccines
2.3 Live and Attenuated Vaccine Sales by Type
2.3.1 Global Live and Attenuated Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Live and Attenuated Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Live and Attenuated Vaccine Sale Price by Type (2018-2023)
2.4 Live and Attenuated Vaccine Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Diagnostic Centers
2.4.4 Research Institute
2.4.5 Others
2.5 Live and Attenuated Vaccine Sales by Application
2.5.1 Global Live and Attenuated Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Live and Attenuated Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Live and Attenuated Vaccine Sale Price by Application (2018-2023)
3 Global Live and Attenuated Vaccine by Company
3.1 Global Live and Attenuated Vaccine Breakdown Data by Company
3.1.1 Global Live and Attenuated Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Live and Attenuated Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Live and Attenuated Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Live and Attenuated Vaccine Revenue by Company (2018-2023)
3.2.2 Global Live and Attenuated Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Live and Attenuated Vaccine Sale Price by Company
3.4 Key Manufacturers Live and Attenuated Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Live and Attenuated Vaccine Product Location Distribution
3.4.2 Players Live and Attenuated Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Live and Attenuated Vaccine by Geographic Region
4.1 World Historic Live and Attenuated Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Live and Attenuated Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Live and Attenuated Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Live and Attenuated Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Live and Attenuated Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Live and Attenuated Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Live and Attenuated Vaccine Sales Growth
4.4 APAC Live and Attenuated Vaccine Sales Growth
4.5 Europe Live and Attenuated Vaccine Sales Growth
4.6 Middle East & Africa Live and Attenuated Vaccine Sales Growth
5 Americas
5.1 Americas Live and Attenuated Vaccine Sales by Country
5.1.1 Americas Live and Attenuated Vaccine Sales by Country (2018-2023)
5.1.2 Americas Live and Attenuated Vaccine Revenue by Country (2018-2023)
5.2 Americas Live and Attenuated Vaccine Sales by Type
5.3 Americas Live and Attenuated Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Live and Attenuated Vaccine Sales by Region
6.1.1 APAC Live and Attenuated Vaccine Sales by Region (2018-2023)
6.1.2 APAC Live and Attenuated Vaccine Revenue by Region (2018-2023)
6.2 APAC Live and Attenuated Vaccine Sales by Type
6.3 APAC Live and Attenuated Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Live and Attenuated Vaccine by Country
7.1.1 Europe Live and Attenuated Vaccine Sales by Country (2018-2023)
7.1.2 Europe Live and Attenuated Vaccine Revenue by Country (2018-2023)
7.2 Europe Live and Attenuated Vaccine Sales by Type
7.3 Europe Live and Attenuated Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Live and Attenuated Vaccine by Country
8.1.1 Middle East & Africa Live and Attenuated Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Live and Attenuated Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Live and Attenuated Vaccine Sales by Type
8.3 Middle East & Africa Live and Attenuated Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Live and Attenuated Vaccine
10.3 Manufacturing Process Analysis of Live and Attenuated Vaccine
10.4 Industry Chain Structure of Live and Attenuated Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Live and Attenuated Vaccine Distributors
11.3 Live and Attenuated Vaccine Customer
12 World Forecast Review for Live and Attenuated Vaccine by Geographic Region
12.1 Global Live and Attenuated Vaccine Market Size Forecast by Region
12.1.1 Global Live and Attenuated Vaccine Forecast by Region (2024-2029)
12.1.2 Global Live and Attenuated Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Live and Attenuated Vaccine Forecast by Type
12.7 Global Live and Attenuated Vaccine Forecast by Application
13 Key Players Analysis
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Information
13.1.2 GlaxoSmithKline Live and Attenuated Vaccine Product Portfolios and Specifications
13.1.3 GlaxoSmithKline Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 GlaxoSmithKline Main Business Overview
13.1.5 GlaxoSmithKline Latest Developments
13.2 Merck & Co.
13.2.1 Merck & Co. Company Information
13.2.2 Merck & Co. Live and Attenuated Vaccine Product Portfolios and Specifications
13.2.3 Merck & Co. Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Merck & Co. Main Business Overview
13.2.5 Merck & Co. Latest Developments
13.3 Pfizer, Inc
13.3.1 Pfizer, Inc Company Information
13.3.2 Pfizer, Inc Live and Attenuated Vaccine Product Portfolios and Specifications
13.3.3 Pfizer, Inc Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Pfizer, Inc Main Business Overview
13.3.5 Pfizer, Inc Latest Developments
13.4 Astellas Pharma Inc
13.4.1 Astellas Pharma Inc Company Information
13.4.2 Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolios and Specifications
13.4.3 Astellas Pharma Inc Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Astellas Pharma Inc Main Business Overview
13.4.5 Astellas Pharma Inc Latest Developments
13.5 Johnson & Johnson
13.5.1 Johnson & Johnson Company Information
13.5.2 Johnson & Johnson Live and Attenuated Vaccine Product Portfolios and Specifications
13.5.3 Johnson & Johnson Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Johnson & Johnson Main Business Overview
13.5.5 Johnson & Johnson Latest Developments
13.6 CSL Limited
13.6.1 CSL Limited Company Information
13.6.2 CSL Limited Live and Attenuated Vaccine Product Portfolios and Specifications
13.6.3 CSL Limited Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 CSL Limited Main Business Overview
13.6.5 CSL Limited Latest Developments
13.7 Emergent BioSolutions, Inc.
13.7.1 Emergent BioSolutions, Inc. Company Information
13.7.2 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolios and Specifications
13.7.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Emergent BioSolutions, Inc. Main Business Overview
13.7.5 Emergent BioSolutions, Inc. Latest Developments
13.8 MedImmune, LLC
13.8.1 MedImmune, LLC Company Information
13.8.2 MedImmune, LLC Live and Attenuated Vaccine Product Portfolios and Specifications
13.8.3 MedImmune, LLC Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 MedImmune, LLC Main Business Overview
13.8.5 MedImmune, LLC Latest Developments
13.9 Sanofi
13.9.1 Sanofi Company Information
13.9.2 Sanofi Live and Attenuated Vaccine Product Portfolios and Specifications
13.9.3 Sanofi Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Sanofi Main Business Overview
13.9.5 Sanofi Latest Developments
13.10 Serum Institute
13.10.1 Serum Institute Company Information
13.10.2 Serum Institute Live and Attenuated Vaccine Product Portfolios and Specifications
13.10.3 Serum Institute Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Serum Institute Main Business Overview
13.10.5 Serum Institute Latest Developments
14 Research Findings and Conclusion
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/